down arrow

Egetis Therapeutics AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0003815604
SEK
4.76
-0.21 (-4.23%)

Dec 04

OME

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Swedish Orphan Biovitrum AB
Camurus AB
BioArctic AB
Swedencare AB
Calliditas Therapeutics AB
Egetis Therapeutics AB
Hansa Biopharma AB
Vicore Pharma Holding AB
Xspray Pharma AB
Infant Bacterial Therapeutics AB
FluoGuide A/S
Why is Egetis Therapeutics AB ?
1
Poor long term growth as Net Sales has grown by an annual rate of -3.42% and Operating profit at -184.58% over the last 5 years
2
Flat results in Mar 25
  • NET SALES(HY) At SEK 23.5 MM has Grown at -47.43%
  • RAW MATERIAL COST(Y) Grown by 69.11% (YoY)
  • INVENTORY TURNOVER RATIO(HY) Lowest at 33.82%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -11.36%, its profits have fallen by -4.8%
4
Below par performance in long term as well as near term
  • Along with generating -11.36% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Egetis Therapeutics AB for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Egetis Therapeutics AB
-11.36%
-0.75
64.32%
OMX Stockholm 30
8.01%
0.44
18.11%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-3.42%
EBIT Growth (5y)
-184.58%
EBIT to Interest (avg)
-68.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.09
Tax Ratio
0.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.99
EV to EBIT
-6.11
EV to EBITDA
-6.11
EV to Capital Employed
8.31
EV to Sales
42.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-136.00%
ROE (Latest)
-94.82%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at SEK -176 MM

CASH AND EQV(HY)

Highest at SEK 623.8 MM

DEBT-EQUITY RATIO (HY)

Lowest at -38.38 %

-21What is not working for the Company
NET SALES(HY)

At SEK 23.5 MM has Grown at -47.43%

RAW MATERIAL COST(Y)

Grown by 69.11% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 33.82%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.66%

INTEREST(Q)

Highest at SEK 11 MM

Here's what is working for Egetis Therapeutics AB
Net Profit
Higher at SEK -176 MM
than preceding 12 month period ended Mar 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (SEK MM)

Cash and Eqv
Highest at SEK 623.8 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -38.38 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Egetis Therapeutics AB
Net Sales
At SEK 23.5 MM has Grown at -47.43%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (SEK MM)

Interest
At SEK 11 MM has Grown at 100%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Interest
Highest at SEK 11 MM
in the last five periods and Increased by 100% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Inventory Turnover Ratio
Lowest at 33.82%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 1.66%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 69.11% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."